AI-generated analysis. Always verify with the original filing.
On March 10, 2026, Aclaris Therapeutics, Inc. sold 5.7 million shares of its common stock for aggregate gross proceeds of $20.0 million pursuant to its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP.